Eiger BioPharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
Eiger BioPharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
艾格生物製藥和 2 其他便士股內人士正在積極購買
The Dow Jones closed slightly higher on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道瓊斯週三收盤略高。當內部人士購買或出售股票時，表明他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易者可以認為這是他們整體投資或交易決策的一個因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是最近一些細價股的著名內幕交易。欲了解更多信息，請查看 本辛加的內幕交易 平台。
Eiger BioPharmaceuticals
艾格生物製藥
- The Trade: Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Director Thomas J. Dietz bought a total of 50,000 shares at an average price of $1.43. To acquire these shares, it cost around $71.58 thousand.
- What's Happening: Eiger BioPharmaceuticals said on January 3, 2023, Sriram Ryali notified the company of resignation as Chief Financial Officer effective Jan. 20, 2023.
- What Eiger BioPharmaceuticals Does: Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies.
- 貿易： 艾格生物製藥股份有限公司 （納斯達克：艾格）董事托馬斯 ·J· 迪茨 買入總共 5 萬股 平均價格為 1.43 美元。要收購這些股票，其成本約為 71.58 萬美元。
- 發生了什麼事： 艾格生物製藥在 2023 年 1 月 3 日表示，斯里拉姆·里亞利（Sriram Ryali）通知該公司辭職，自 2023 年 1 月 20 日起生效。
- 艾格生物製藥有什麼作用： Eiger Bioharmaceuticals Inc 是一家商業階段的生物製藥公司，專注於針對嚴重，罕見和超罕見疾病的藥物開發和商業化，具有高尚未得到滿足的醫療需求，並且沒有經過批准的療法。
Adamas One
阿達姆斯一號
- The Trade: Adamas One Corp. (NASDAQ:JEWL) President and CEO John Grdina acquired a total of 40,000 shares at an average price of $2.67. The insider spent around $106.78 thousand to buy those shares.
- What's Happening: On the heels of its initial public offering, Adamas One reported $1.78 million in initial lab grown diamond sales for FY22.
- What Adamas One Does: Adamas One Corp is a high-tech diamond company that uses its proprietary technology to produce high-quality, single-crystal diamonds and diamond materials through a CVD process, which it refers to as Diamond Technology.
- 貿易: 阿達姆斯一號 (NASDAQ: JWL) 總裁兼首席執行官約翰·格迪納 購入總共 4 萬股 平均價格為 2.67 美元。內部人士花費了大約 106.78 萬美元購買這些股票。
- 發生了什麼：在其首次公開發行的後台上，Adamas One 報告了 22 財年最初的實驗室種植鑽石銷售 1.78 萬美元。
- 阿達姆斯一個做什麼: Adamas One Corp 是一家高科技鑽石公司，利用其專有技術，通過 CVD 工藝生產高品質的單晶鑽石和鑽石材料，稱為鑽石技術。
Check This Out: 5 Most Expensive Energy Stocks You Should Worry About
看看這個： 您應該擔心的 5 種最昂貴的能源股票
Biomerica
生物美利
- The Trade: Biomerica, Inc. (NASDAQ:BMRA) CEO Zackary Irani acquired a total of 2,000 shares at an average price of $2.81. To acquire these shares, it cost around $5.62 thousand.
- What's Happening: Biomerica, last month, received Kingdom of Saudi Arabia Food And Drug Administration and Ministry of Health approval for colorectal screening and breast screening tests in Saudi Arabia and UAE.
- What Biomerica Does: Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions.
- 貿易: 生物美利科技股份有限公司 (納斯達克:BMRA) 首席執行官扎卡里·伊拉尼 購入合共 2,000 股股份 平均價格為 2.81 美元。要收購這些股票，其成本約為 5.62 萬美元。
- 發生了什麼: Biomerica 上個月獲沙特阿拉伯王國食品藥品監督管理局和衛生部批准在沙特阿拉伯和阿聯酋進行結直腸篩查和乳房篩查測試。
- 生物美利做什麼: Biomerica Inc. 從事醫療診斷產品的開發、製造和銷售，專為慢性疾病和醫療狀況而設計的早期檢測和監測。
Don't forget to check out our premarket coverage here
不要忘記在這裡查看我們的售前覆蓋範圍
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。